Budweiser Brewing Co APAC Stock (OTC: BDWBF)

Dernières nouvelles pour Budweiser Brewing Co APAC (OTC:BDWBF) Stock

Budweiser APAC is the largest brewer in Asia by retail sales value and the second largest by volume, according to Euromonitor. After 10% of the business was listed on the Hong Kong exchange in 2019, parent company Anheuser-Busch InBev owns close to 90% of the company's equity.Budweiser APAC's largest markets are China (roughly 80% of 2023 revenue), South Korea (12%), and India (6%). The remaining 2% comprises Japan, New Zealand, and other export markets in the Asia-Pacific region. The company predominantly produces, imports, markets, distributes, and sells a portfolio of more than 50 beer brands, both owned and licensed, including global brands Budweiser, Stella Artois, and Corona along with multicountry brands and local brands such as Hoegaarden, Cass and Harbin.

BUDWEISER BREWING CO by BUDWEISER BREWING CO APAC LTD.

Budweiser Brewing Co APAC Ltd

WIIM

VNET

VNET Group shares are trading higher after the company reported Q3 EPS and revenue that rose year-over-year.

Barclays analyst Brian Morton maintains Bank of Montreal (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BMO#TSX">BMO</a>) with a Overweight and raises the price target from C$126 to C$143.

News

Price Target

Analyst Ratings

TSX:BMO

Barclays Maintains Overweight on Bank of Montreal, Raises Price Target to C$143

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

JAZZ

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Universal Technical Institute shares are trading higher after the company reported better-than-expected Q4 EPS and sales, and provided FY2024 revenue guidance above analyst estimates.

AppLovin shares are trading higher after the company priced a public offering of $3.55 billion in senior notes.

In Anaheim at the recent <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California </a>event, seasoned cannabis entrepreneur Seth Yakatan shared his perspective on the cannabis industry's current landscape and future potential. 
Despite recent shifts in cannabis stock prices, Yakatan believes the sector remains fundamentally stable. "The technical fundamentals of the sector pretty much remained the same," he noted, adding that he saw the price drop as an opportunity and "just bought more stocks cheaper."
<h4 class="wp-block-heading">Federal Policy and a Cautious Outlook</h4>
Looking ahead, Yakatan discussed the impact of upcoming federal decisions on the cannabis industry. He remains "cautiously optimistic" but believes it could be March before any clear direction emerges. 
Yakatan highlighted three key areas to watch: the selection of a new Attorney General, possibly reclassifying cannabis to Schedule III and ongoing legislative changes in states like Pennsylvania. "Anything other than that's probably just speculation," he remarked, stressing that the path forward depends on these developments.
<h4 class="wp-block-heading">California's Market Leads the Way</h4>
Yakatan also expressed confidence in California's enduring position as a leader in the U.S. cannabis market, calling it "still the biggest cannabis market in the United States." 
Although he acknowledged challenges within California's market, he emphasized the dedication of long-standing businesses that continue to secure investment and make strides in the industry. "I don't see that dynamic changing," Yakatan stated, underscoring his confidence in California's cannabis market to continue thriving.
Yakatan's observations at the event reflected the optimism shared by many industry experts, signaling a resilient future for cannabis even as it faces a complex regulatory environment.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111313/exclusive-fluent-launches-new-cannabis-concentrates-line-for-medical-marijuana-patients-in-florida">FLUENT Launches New Cannabis Concentrates Line For Medical Marijuana Patients In Florida</a></li>
</ul>
Image: AI-Generated Image

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

California's Cannabis Future: Why One Expert Believes The Market Will Hold Strong

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $166 to $163.

Reiteration

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $163

Barclays analyst Alex Scott maintains Arthur J. Gallagher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) with a Equal-Weight and raises the price target from $300 to $308.

Barclays Maintains Equal-Weight on Arthur J. Gallagher, Raises Price Target to $308

Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are trading higher on Thursday. The company announced it submitted a <a href="https://www.benzinga.com/pressreleases/24/11/b42099063/super-micro-computer-inc-nasdaq-non-compliance-update">compliance plan to the Nasdaq</a>.
What Happened: After the market close on Wednesday, Super Micro said it submitted a compliance plan to the Nasdaq after receiving a notification letter that it was not in compliance with the Nasdaq&#8217;s timely filing rule. The plan was submitted on Monday with respect to supporting the company&#8217;s request for an extension to regain compliance.
Super Micro said in the compliance plan that it believes it will be able to file both its annual report for the fiscal year ended June, 30 2024 and its quarterly report for the period ended Sept. 30, 2024 within the discretionary period that can be granted by the Nasdaq.
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42109965/baidus-q3-earnings-revenue-slides-weak-online-ads-market-impact-margins">Baidu&#8217;s Q3 Earnings: Revenue Slides, Weak Online Ads Market Impact Margins</a>
The update comes after the company&#8217;s independent auditor resigned at the end of October over&nbsp;<a href="https://www.benzinga.com/quote/SMCI" target="_blank" rel="noreferrer noopener">governance and transparency concerns</a>. 
Super Micro on Monday announced that it <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42069253/supermicro-stock-is-rising-tuesday-whats-going-on">appointed BDO USA</a> as its new independent auditor, effective immediately.
&#8220;BDO is a highly respected accounting firm with global capabilities.&nbsp;This is an important next step to bring our financial statements current, an effort we are pursuing with both diligence and urgency,&#8221; said&nbsp;Charles Liang, president and CEO of SuperMicro.
Super Micro has faced significant selling pressure since the company&#8217;s auditor raised concerns. The stock traded all the way down to around $17.25 per share last week before bouncing back. Super Micro shares are now up more than 43% over the past five trading sessions.
SMCI Price Action: Super Micro shares were up 5.23% at $27.18 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

SMCI

Super Micro Computer Stock Is Rallying Thursday: What's Going On?

LAZR

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Piper Sandler analyst Adam Butler assumes Farmers National Banc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMNB#NASDAQ">FMNB</a>) with a Neutral rating and announces Price Target of $17.

Initiation

FMNB

Piper Sandler Assumes Farmers National Banc at Neutral, Announces Price Target of $17

Barclays analyst Alex Scott maintains Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) with a Overweight and raises the price target from $394 to $440.

Barclays Maintains Overweight on Aon, Raises Price Target to $440

Agrify Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFY#NASDAQ">AGFY</a>) shares are trading lower by 23.9% to $29.50 Thursday morning after the company announced it secured approximately $25.9 million through a <a href="https://www.benzinga.com/pressreleases/24/11/g42108171/agrify-announces-25-9-million-non-brokered-private-placement">non-brokered private placement</a>.
What Happened: The deal, priced at $22.30 per share, involves securities purchase agreements with institutional and accredited investors. The proceeds will support general corporate purposes, including working capital and business development.
The private placement, expected to close on November 21, includes participation from Chairman and Interim CEO Benjamin Kovler, who purchased 10,000 shares at $38.76 each in accordance with Nasdaq requirements.
Kovler emphasized the strategic significance of the funding, calling it a &#8220;strong move&#8221; for the company and shareholders. &#8220;We plan to channel this capital into areas within our expertise to maximize shareholder value,&#8221; he said, highlighting optimism around cannabis and hemp consumer trends. 
Kovler also confirmed progress on the company&#8217;s pending Señorita transaction, which is anticipated to close by year-end.
Read Also: <a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a>
<h2 class="wp-block-heading">Should I Sell My AGFY Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
AGFY has a 52-week high of $42.00 and a 52-week low of $2.71.

AGFY

Why Agrify (AGFY) Stock Is Getting Hammered

CGNT

Cognyte Secures $2M+ Follow-On Order From Leading North American Law Enforcement Agency, Bringing Total Investment To $3M As Agency Replaces Incumbent Provider For Enhanced Threat Detection And Operational Intelligence

Warner Music Group shares are trading lower after the company reported worse-than-expected Q4 EPS results.

KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) shares are trading higher premarket on Thursday. The company led a $370 million growth investment in Lighthouse, a commercial intelligence platform<a href="https://www.benzinga.com/pressreleases/24/11/b42104948/lighthouse-announces-370-million-series-c-investment-led-by-kkr-to-accelerate-platform-innovation-" target="_blank" rel="noreferrer noopener"> for the travel and hospitality industry</a>.
This funding will propel Lighthouse&#8217;s efforts to transform commercial strategy within the $15 billion travel and hospitality technology sector. 
The investment will be allocated towards further product innovation, strategic acquisitions, and expanding Lighthouse's global presence.
Notably, KKR has a proven track record of investing $23 billion in technology-focused growth companies since 2010, which will help Lighthouse expand globally.
Sean Fitzpatrick, CEO of Lighthouse said, &#8220;This investment by KKR significantly accelerates our ability to enhance our commercial platform through expanded AI capabilities and additional data sets, enabling us to better serve our existing customers while continuing to expand across the hospitality market.&#8221;
Yesterday, KKR launched the second stage of its tender offer for FUJI SOFT INCORPORATED shares and share options, which started on November 20, 2024, and will <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42083136/kkr-commences-second-tender-offer-for-fuji-soft" rel="noreferrer noopener">run until December 19, 2024</a>.
The tender offer price is 9,451 yen per common share and varies for share options, with prices set at 1,197,200 yen for the 5th Series, 1,059,800 yen for the 6th Series, and 293,200 yen for the 7th Series.
Investors can gain exposure to KKR via&nbsp;FM Focus Equity ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMCX#NYSE">FMCX</a>) and&nbsp;EA Series Trust WHITEWOLF Publicly Listed Private Equity ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/LBO#BATS">LBO</a>).
Price Action: KKR shares are up 1.19% at $153.99&nbsp;premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/ma/24/11/42025534/deal-dispatch-shell-unilever-and-more-are-on-the-sell-side-the-onion-makes-alex-jones-cry-foul" target="_blank" rel="noreferrer noopener">Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul</a></li>
</ul>

Equities

Northern Lights Fund Trust IV FMC Excelsior Focus Equity ETF

FMCX

KKR Inks $370 Million Investment, Propels Lighthouse's Global Hospitality Ambitions

Roth MKM analyst Bill Kirk maintains Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral and lowers the price target from $157 to $131.

Roth MKM Maintains Neutral on Target, Lowers Price Target to $131

CETY

Clean Energy Technologies shares are trading higher after the company announced a strategic partnership with METIS Power to develop advanced microgrid solutions for AI data centers and cryptocurrency mining operations.

Comments

Budweiser Brewing Co APAC

Actualités

Dernières nouvelles pour Budweiser Brewing Co APAC (OTC:BDWBF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL